Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

‘Superbug’ Fungus Emerges as New Menace in US Hospitals, Mostly NY and NJ

New York, NY, April 27, 2017 — The Associated Press reports that a “superbug” fungus is emerging as a new menace in U.S. hospitals, mostly in New York and New Jersey.

First identified in Japan in 2009, the fungus has spread to more than a dozen countries around the globe.  The oldest of the 66 cases reported in the U.S. dates back to 2013, but most were reported in the last year.

The fungus called Candida auris is a harmful form of yeast.

Scientists say it can be hard to identify with standard lab tests. U.S. health officials sounded alarms last year because two of the three kinds of commonly used antifungal drugs have little effect.

“It’s acting like a superbug” bacteria, said Dr. Paige Armstrong of the Centers for Disease Control and Prevention (CDC).

Most vulnerable are fragile hospital patients — particularly newborns and the elderly. It tends to be diagnosed in patients after they’ve been in hospitals for several weeks. The fungus can infect wounds, ears and the bloodstream.

A study presented at a CDC conference this week detailed how researchers traveled to South America to help investigate an outbreak in three Colombia cities.

They found the fungus on surfaces in hospital rooms and on the skin of nurses and patients — even after patients were treated with antifungal medications.

For the full AP story, click here.